Henning Sand Christensen

Minimal Residual Disease (MRD) follow up of MM patients obtaining stringent complete remission (sCR) in the NMSG/EMN02 clinical trial – defining sCR numbers and prediction of disease progression by multiparametric flow cytometry (MFC).

Johnsen, H. E., Schmitz, A., Bødker, J. S., Sonneveld, P., Hofste op Bruinink, D., van der Holt, B., van der Velden, V. H. J., Abildgaard, N., Ahlberg, L., Andersen, N., Andreasson, B., Brandefors, L., Christiansen, H. B., Faxoe, S., Fransson, C., Friestad, M., Gregersen, H., Hammerlund, Y., Hansson, M., Haukaas, E., & 26 othersHector, M., Helleberg, C., Holst, M., Jönsson, A. K., Karlsson, V., Klostergaard, A., Kjær, S., Lauri, B., Lenhoff, S., Lonn, I., Myhr, E., Pedersen, B. H., Renna, R., Sjøgren, T. V., Svirskaite, A., Szatkowski, D. L., Vangsted, S., Waage, A., Schjesvold, F. H., Mellqvist, U-H., Høholt, H., Madsen, L. H., Christensen, H. S., Brøndum, R. F., Bøgsted, M. & Dybkær, K., 2018, In: Haematologica. 103, S1, p. 13 1 p., BA6.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review